Showing results (1601-1610 of 2,234) with videos related to
Sort By:
Pageof 224
Cancer Biotherapy & Radiopharmaceuticals|August 9, 2020
Long Noncoding RNA TP53TG1 Contributes to Radioresistance of Glioma Cells Via miR-524-5p/RAB5A AxisWenjin Gao, Mu Qiao, Kuan LuoCancer Biotherapy & Radiopharmaceuticals|July 24, 2020
Long Noncoding RNA NEAT1 Contributes to the Tumorigenesis of Colorectal Cancer Through Regulating SLC38A1 Expression by Sponging miR-138Sisi Wang, Hui Du, Peisen SunCancer Biotherapy & Radiopharmaceuticals|January 22, 2014
Numerical comparison of iodine-based and indium-based antibody biodistributionsLawrence E Williams, Anna M Wu, Vania E Kenanova, et al.Cancer Biotherapy & Radiopharmaceuticals|February 26, 2015
Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapyMarian Meckel, Alexander Nauth, Jan Timpe, et al.Cancer Biotherapy & Radiopharmaceuticals|March 10, 2015
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate CancerHossein Jadvar, Sudha Challa, David I Quinn, et al.Cancer Biotherapy & Radiopharmaceuticals|March 10, 2015
Cancer vaccines: can they improve survival?Robert O DillmanCancer Biotherapy & Radiopharmaceuticals|March 12, 2015
TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cellsQi-feng Cao, Su-bo Qian, Ning Wang, et al.Cancer Biotherapy & Radiopharmaceuticals|March 27, 2015
Decreased Expression of miR-15b in Human Gliomas is Associated with Poor PrognosisGuan Sun, Shushan Yan, Lei Shi, et al.Cancer Biotherapy & Radiopharmaceuticals|July 10, 2020
Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O6-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53Samereh Dehghani-Soltani, Seyed Hassan Eftekhar-Vaghefi, Abdolreza Babaee, et al.Cancer Biotherapy & Radiopharmaceuticals|July 19, 2012
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?Robert O Dillman, Neil M Barth, Louis A VanderMolen, et al.Pageof 224